计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| D126373-5mg |
5mg |
现货 ![]() |
| |
| D126373-10mg |
10mg |
现货 ![]() |
| |
| D126373-50mg |
50mg |
现货 ![]() |
|
| 英文别名 | BDBM185674 | 4-[4-[(5-Tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide,4-methylbenzenesulfonic acid;4-[4-[(5-Tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-c |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | DCC-2036 (Rebastinib) |
| 生化机理 | 领先的 "开关控制 "抑制剂 DCC-2036 通过诱导 II 型非活性构象,有效抑制未磷酸化和磷酸化 ABL1,并对大多数临床相关的 CML 抗性突变体(包括 T315I)保持疗效。DCC-2036 可抑制 ABL 和 ABLT315I 酶的自身磷酸化,这种活性与对表达 BCR-ABL(IC50:19 nmol/L)、BCR-ABLT315I(IC50:63 nmol/L)和大多数激酶域突变体的 Ba/F3 细胞的选择性疗效一致。这些研究结果支持将 DCC-2036 作为治疗难治性 CML 的重要新药继续进行评估。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 酪氨酸蛋白激酶 ABL 抑制剂 |
| 纯度 | ≥98% |
| ALogP | 4.9 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504769950 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide |
| INCHI | 1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40) |
| InChi Key | WVXNSAVVKYZVOE-UHFFFAOYSA-N |
| Smiles | CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5 |
| Isomeric SMILES | CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5 |
| 分子量 | 553.59 |
| Reaxy-Rn | 15642205 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=15642205&ln= |
| 溶解性 | DMSO 111 mg/mL Water <1 mg/mL Ethanol 16 mg/mL |
|---|---|
| 分子量 | 553.600 g/mol |
| XLogP3 | 4.900 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 7 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 553.224 Da |
| 单同位素质量Monoisotopic Mass | 553.224 Da |
| 拓扑极表面积Topological Polar Surface Area | 123.000 Ų |
| 重原子数Heavy Atom Count | 41 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 904.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ. (2011) Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.. Clin Cancer Res, 17 (2): (212-21). [PMID:21098337] |
| 2. Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, Haack T, Hood MM, Jones J, Lord JW, Lu WP et al.. (2011) Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.. Cancer Cell, 19 (4): (556-68). [PMID:21481795] |
| 3. Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW et al.. (2011) The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.. Cancer Res, 71 (9): (3189-95). [PMID:21505103] |
| 4. Patel PR, Sun H, Li SQ, Shen M, Khan J, Thomas CJ, Davis MI. (2013) Identification of potent Yes1 kinase inhibitors using a library screening approach.. Bioorg Med Chem Lett, 23 (15): (4398-403). [PMID:23787099] |
| 5. Harney AS, Karagiannis GS, Pignatelli J, Smith BD, Kadioglu E, Wise SC, Hood MM, Kaufman MD, Leary CB, Lu WP et al.. (2017) The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.. Mol Cancer Ther, 16 (11): (2486-2501). [PMID:28838996] |